Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
An update from Aspira Women’s Health ( (AWHL) ) is now available.
On March 5, 2025, Aspira Women’s Health Inc. entered into a securities purchase agreement with existing accredited shareholders for a private placement of $1,370,000 in Senior Secured Convertible Promissory Notes, which have since been converted into units of common stock and warrants. On September 19, 2025, the company amended the agreement to exclude certain securities from ‘Exempt Issuance,’ required filing a registration statement, and allowed purchasers to appoint directors to the board. The amendment also adjusted terms of the warrants, including a fixed exercise price and extended term.
The most recent analyst rating on (AWHL) stock is a Hold with a $3.00 price target. To see the full list of analyst forecasts on Aspira Women’s Health stock, see the AWHL Stock Forecast page.
Spark’s Take on AWHL Stock
According to Spark, TipRanks’ AI Analyst, AWHL is a Neutral.
The company’s challenging financial position, marked by unprofitability and negative equity, significantly impacts its stock score. While technical indicators show some positive momentum, the lack of profitability and adverse corporate events weigh heavily on the overall assessment.
To see Spark’s full report on AWHL stock, click here.
More about Aspira Women’s Health
Aspira Women’s Health Inc. operates in the healthcare industry, focusing on providing innovative diagnostic solutions for women’s health. The company specializes in developing and commercializing diagnostic tests aimed at improving the detection and management of gynecologic diseases, with a particular emphasis on ovarian cancer.
Average Trading Volume: 104,293
Technical Sentiment Signal: Sell
Current Market Cap: $18.54M
For detailed information about AWHL stock, go to TipRanks’ Stock Analysis page.